VERA

Vera Therapeutics Inc

VERA.US veratx.com
33.60
-0.18 (-0.53%)
USD · NASDAQ
52-week range
22.72
56.05
Trading at 33% of the 52-week range
Market Cap
2.43B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
5.67
Div. Yield
N/A
% Institutions
117.97%
% Insiders
0.954%

1 Year

+37.9%

3 Year

+76.8%

10 Year

+192.2%
Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Company Information

Company Name
Vera Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92337R1014
CIK: 0001831828
CUSIP: 923351100
Currency: USD
Full Time Employees: 361
Phone: 650 770 0077
Website: veratx.com
Fiscal Year End: December
IPO Date: May 14, 2021
Description:

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Address:

2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

People

Directors & Officers

Name Title Year Born
Dr. Marshall W. Fordyce M.D. Founder, President, CEO & Director 1975
Mr. Sean P. Grant M.B.A. Chief Financial Officer 1985
Mr. David L. Johnson M.B.A. Chief Opearating Officer 1970
Dr. Robert M. Brenner M.D. Chief Medical Officer 1968
Mr. Joseph R. Young M.B.A. Senior VP of Finance & Chief Accounting Officer 1972
Ms. S. Sandra Park J.D. Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations NA
Dr. Jane Wright-Mitchell J.D., Pharm.D. Chief Legal Officer & Secretary 1969
Ms. Debra Charlesworth Vice President of Corporate Communications NA
Ms. Emma Haywood Vice President of Marketing NA
Mr. Tom Doan Executive Vice President of Development Operations 1972

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 14, 2026 Marshall Fordyce N/A Sale 22.95K $44.05 $1.01M
Feb 23, 2026 David Lee Johnson N/A Sale 2.58K $41.98 $108.27K
Feb 23, 2026 Joseph R Young N/A Sale 3.12K $41.98 $130.85K
Feb 23, 2026 Laurence Matthew Skelton N/A Sale 1.58K $41.98 $66.41K
Feb 23, 2026 Marshall Fordyce N/A Sale 16.93K $41.98 $710.51K
Feb 23, 2026 Robert Brenner N/A Sale 2.15K $41.98 $90.30K
Feb 23, 2026 Sean Grant N/A Sale 4.95K $41.98 $207.76K
Feb 23, 2026 William D Turner N/A Sale 2.19K $41.98 $91.81K
Dec 11, 2025 Patrick G Enright N/A Purchase 5.88K $42.50 $249.99K
Nov 11, 2025 Joseph R Young N/A Sale 15.00K $29.06 $435.90K
Jun 24, 2025 Patrick G Enright N/A Purchase 40.61K $22.35 $907.57K
Jun 23, 2025 Patrick G Enright N/A Purchase 209.39K $20.87 $4.37M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
venBio Select Advisor LLC 5.89M Mar 31, 2026 8.17% $2.33 0.00%
BlackRock Inc 5.09M Mar 31, 2026 7.06% $0.00 5.44%
T. Rowe Price Associates, Inc. 4.57M Mar 31, 2026 6.35% $0.02 -16.26%
Deep Track Capital, LP 4.00M Jun 30, 2026 5.55% $2.50 -2.58%
Deerfield Management Co 3.72M Mar 31, 2026 5.17% $1.77 -8.32%
State Street Corp 3.36M Mar 31, 2026 4.67% $0.00 25.67%
Kynam Capital Management, LP 2.89M Jun 30, 2026 4.01% $6.85 -14.95%
Sofinnova Ventures 2.79M Mar 31, 2026 3.88% $4.27 0.00%
Vanguard Capital Management, LLC 2.68M Mar 31, 2026 3.72% $0.00 0.00%
FMR Inc 2.68M Mar 31, 2026 3.71% $0.01 -7.26%
Eversept Partners, LP 2.21M Jun 30, 2026 3.07% $4.93 1.82%
Logos Global Management LP 2.20M Jun 30, 2026 3.05% $4.06 0.00%
Integral Health Asset Management, LLC 1.75M Jun 30, 2026 2.43% $2.97 9.38%
Bellevue Group AG 1.71M Mar 31, 2026 2.37% $1.64 0.74%
Geode Capital Management, LLC 1.57M Mar 31, 2026 2.18% $0.00 8.66%
Vestal Point Capital LP 1.37M Mar 31, 2026 1.90% $1.54 148.76%
AllianceBernstein L.P. 1.31M Mar 31, 2026 1.82% $0.02 7.84%
Frontier Capital Management CO Inc 1.30M Jun 30, 2026 1.80% $0.52 134.89%
Pictet Asset Manangement SA 1.25M Jun 30, 2026 1.73% $0.05 18.81%
Point72 Asset Management, L.P. 1.21M Mar 31, 2026 1.68% $0.06 -30.35%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 2.79M 3.87% ▼ 1.06% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.94M 2.70% ▲ 0.46% Jul 31, 2026
3 iShares Russell 2000 ETF 1.64M 2.28% ▼ 0.57% Aug 31, 2026
4 Fidelity Growth Compy Commingled Pl S 1.20M 1.67% ▲ 0.00% Jul 31, 2026
5 US Small-Cap Growth II Equity Comp 1.01M 1.41% ▼ 9.74% Jun 30, 2026
6 T. Rowe Price New Horizons 961.65K 1.33% ▼ 5.21% Jul 31, 2026
7 Fidelity Growth Company Fund 871.55K 1.21% ▲ 0.00% Jul 31, 2026
8 International Biotechnology Ord 787.64K 1.09% ▲ 54.31% Jul 31, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 760.67K 1.06% ▲ 0.17% Jul 31, 2026
10 Fidelity Small Cap Index 693.06K 0.96% ▲ 12.35% Jun 30, 2026

Financial Highlights

Market Cap: $2.43B
EBITDA: $-415.22M
Book Value: $5.67
Earnings/Share: $-5.87
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -46.76%
ROE (TTM): -91.75%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $2.12B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 72.06M
Shares Float: 52.39M
% Insiders: 0.954%
% Institutions: 117.97%
Short % Float: 26.56%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-468.00K
Gross Profit
subtotal
$-468.00K
SG&A
adjust
$-100.22M
R&D
adjust
$-215.26M
Operating Income
subtotal
$-315.47M
Other / Non-Operating Items
adjust
$15.86M
Net Income
subtotal
$-299.62M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VERA.US!